First Patients in the S.I.LE.N.C.E. Trial Underwent Elevoplasty Procedures Last Friday
IRVINE, CA (March 13th, 2017) – Zelegent, Inc., a clinical-stage medical technology company developing innovative tools for otolaryngologist sleep specialists, today announced the beginning of enrollment in its multi-center pivotal snoring reduction trial, the SILENCE study. The trial will evaluate the safety and efficacy of Snoring Intervention via Elevoplasty™ in a Non-surgical Clinical Environment (S.I.LE.N.C.E.).
ALPHAEON and Zelegent Announce Exclusive Global Agreement to Commercialize Office-Based Snoring Therapy
IRVINE, Calif., Dec. 15, 2015 ALPHAEON Corporation, a subsidiary of Strathspey Crown Holdings LLC, and Zelegent, Inc. jointly announced today that the two companies have entered into an exclusive worldwide agreement to bring Zelegent’s office-based Elevoplasty technology to board certified sleep specialists. Under the terms of the agreement, which includes product development and commercialization, ALPHAEON became the lead investor in Zelegent’s Series A Financing. The amount of the investment was not disclosed.
Outcomes data presented today at the 3rd Congress of European Otorhinolaryngology and Head and Neck Surgery in Prague, Czech Republic
IRVINE, CA (June 8, 2015) – Zelegent, Inc. (formerly Snorx, Inc.), presented clinical outcomes from its pilot clinical study today at the 3rd Congress of European Otorhinolaryngology and Head and Neck Surgery (ORL-HNS) in Prague, Czech Republic (http://www.europeanorl-hnsprague2015.com) by Dr. Yosef Krespi, Chairman of the Board of Zelegent. The clinical trial data presented included post-op and 4-6-month follow up results for the first 20 of the 45 subjects treated for snoring with the prototype version of Zelegent’s first device. The study was conducted at the New York Head and Neck Institute pursuant to a protocol approved by the Western Institutional Review Board. The endpoints included improvements in quality of life, sleep quality, and the elimination of snoring. The quantitative results, which were unveiled at 3:00 pm Central European today, showed that for the first 20 study subjects who have completed their 4-6 month follow-up visit:
IRVINE, CA (June 2, 2015) – Zelegent, Inc. (formerly Snorx, Inc.), announced today that five of the foremost experts in sleep disorder therapy have joined its clinical advisory board, the company has joined the EvoNexus incubator program, and the company plans to present results from its first clinical trial next week. The company is developing a surgical tool that allows otolaryngologist (ENT) sleep specialists to perform an in-office procedure that requires no general anesthesia, and may alleviate snoring by shortening, suspending, and stiffening a patient’s soft palate.
IRVINE, CA (May 12, 2015) – Snorx, Inc., the developer of an innovative minimally invasive surgical interventional anti-snoring device, today reported that after a re-branding exercise led by branding expert Dean del Sesto and his firm Brevity, Inc., the Company’s Board of Directors has voted to change the name of the company to Zelegent, Inc.
Snorx, Inc. Taps Medical Technology Industry Veteran Alexander K. Arrow, MD as Chief Executive Officer
LAKE FOREST, CA (January 7, 2015) – Snorx, Inc., the developer of an innovative minimally invasive surgical interventional anti-snoring device, today reported that Alexander K. Arrow, M.D. has been appointed Chief Executive Officer and will be leading the company as it enters its regulatory submission phase and prepares to manufacture its first product.